INTRANASAL DRUG DELIVERY DEVICES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Intranasal Drug Delivery Devices Market, By Dosage Form (Nasal Spray, Nasal Drop, Nasal Gel, Nasal Powder), By Application (Chronic Obstructive Pulmonary Disease (COPD), Rhinitis, Cystic Fibrosis, Nasal Congestion, Asthma, Others), By End User (Ambulatory Surgical Centers, Clinics, Hospitals, Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In April 2024, Bespak completed its separation from Recipharm to establish itself as an independent organization dedicated to developing drug-device combination products and drug delivery devices specifically for pulmonary and nasal inhalation
In November 2023, Hovione, a specialized integrated CDMO renowned for spray drying and particle engineering, launched an enhancement to its nasal drug delivery capabilities. This expansion includes a new line of advanced nasal powder delivery devices developed in collaboration with IDC. Intranasal drug delivery is increasingly favored over traditional methods for its ease, safety, and rapid onset of action, making it suitable for both local and systemic drug administration.
In March 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant), marking it as the first and only nasal spray calcitonin gene-related peptide (CGRP) receptor antagonist for treating acute migraine in adults, with or without aura
In January 2023, Aptar Pharma, a division of AptarGroup, Inc. and a worldwide leader in drug delivery systems, services, and active material science solutions, introduced APF Futurity. Its inaugural metal-free, multidose nasal spray pump is designed for dispensing nasal saline and similar over-the-counter (OTC) formulations.